Buy Genferon vaginal/rectal suppositories 500t IU No. 10 in pharmacies

Features of the composition of Genferon

The instructions indicate that the medicine is prepared in suppositories; the main active ingredients are presented:

• human recombinant interferon alpha-2b;
• taurine;
• benzocaine.

The role of additional components is given to macrogol 1500, citric acid, dextran 60000, solid fat, sodium hydrogen citate, purified water, polysorbate 80, emulsifier T2.

Genferon is available in whitish or yellowish suppositories, packaged in cardboard packs of 5 or 10 pieces.

Genferon light supp 125 thousand IU N10 (OTISI)

Pharmaceutical group: Interferon. Immunomodulatory drug with antiviral effect. Pharmaceutical action: Immunomodulatory, antiviral, antibacterial, antiproliferative, regenerating. Immunobiological properties Genferon Light is a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic effects. The composition of the drug Genferon Light includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene was introduced using genetic engineering methods. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T killer cells, NK cells (natural killer cells), increased differentiation of B lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon. Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. Pharmacokinetics: With rectal administration of the drug, high bioavailability (more than 80%) of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the vaginal mucosa, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect due to the low absorption capacity of the vaginal mucosa is insignificant. Cmax of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of elimination is renal catabolism. T1/2 is 12 hours, which necessitates the use of the drug 2 times a day. When administered intranasally, due to the high concentration at the site of infection, a pronounced local antiviral and immunostimulating effect is achieved. Systemic absorption of the drug is insignificant - the low bioavailability of drugs when administered intranasally is associated with the functioning of a special family of proteins of 25 proteins that are part of the nasal mucosa and control the transport of all molecular and cellular objects that penetrate the mucosa. At the same time, a certain amount of the drug enters the systemic bloodstream, thereby achieving a systemic immunomodulatory effect.

Contraindications and indications from the instructions for Genferon

Rectal or vaginal suppositories are prescribed for adults and children. In the latter case, the drug Genferon Light is used. The medication is suitable for the complex treatment of individual pathologies that provoke inflammation of the genitourinary

department:

• for chlamydia, genital herpes;
• mycoplasmosis, ureaplasmosis;
• gardnerellosis, HPV;
• trichomoniasis, bacterial vaginosis;
• cervical erosion, vulvovaginitis;
• cervicitis, adnexitis;
• urethritis, balanitis, bartholinitis;
• prostatitis, balanoposthitis;
• thrush.

Genferon is contraindicated in patients with individual intolerance to the component composition in the first 4 months of pregnancy. Caution during therapeutic procedures is necessary for patients with acute diseases affecting the immune system.

Buy Genferon vaginal/rectal suppositories 500t IU No. 10 in pharmacies

Genferon Buy Genferon in pharmacies

DOSAGE FORMS suppositories 500000IU

MANUFACTURERS Biocad CJSC (Russia)

GROUP Antiviral agents of different groups

COMPOSITION Active substances: recombinant human interferon alpha-2, taurine, anesthesin.

INTERNATIONAL NON-PROPENTED NAME no

PHARMACOLOGICAL ACTION Genferon is a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic effects. Interferon alpha-2 has antiviral, antimicrobial and immunomodulatory effects. Under the influence of interferon alpha-2, the activity of natural killer cells, T-helper cells, phagocytes, as well as the intensity of differentiation of B-lymphocytes in the body increases. Activation of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of primary pathological foci and ensures restoration of the production of secretory immunoglobulin A. Interferon alpha-2 also directly inhibits the replication and transcription of viruses and chlamydia. Taurine, which is part of the drug, has regenerating, reparative, membrane- and hepatoprotective, antioxidant, and anti-inflammatory properties. Anestezin is a local anesthetic. Reduces the permeability of the cell membrane to sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, and blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses at the endings of sensory nerves and their conduction along nerve fibers. When administered vaginally or rectally, interferon alfa-2 is absorbed through the mucous membrane, enters the surrounding tissues, and enters the lymphatic system, providing a systemic effect. Also, due to partial fixation on the cells of the mucous membrane, it has a local effect.

INDICATIONS FOR USE As part of complex therapy for infectious and inflammatory diseases of the urogenital tract: genital herpes, chlamydia, ureaplasmosis, mycoplasmosis, recurrent vaginal candidiasis, gardnerellosis, trichomoniasis, papillomavirus infections, bacterial vaginosis, cervical erosion, cervicitis, vulvovaginitis, barto linitis, adnexitis, prostatitis, urethritis, balanitis, balanoposthitis.

CONTRAINDICATIONS Individual intolerance to interferon and other substances included in the drug. Use with caution during exacerbation of allergic and autoimmune diseases. Use in the second half of pregnancy is allowed if the benefits of the therapy outweigh the possible risk to the fetus.

SIDE EFFECTS Allergic reactions, namely skin rashes and itching. These phenomena are reversible and disappear 72 hours after stopping administration or reducing the dose. There may also be phenomena that occur with the use of all types of interferon alpha-2, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia, but they occur more often with administering a dose of more than 10 million IU daily.

INTERACTION Genferon is most effective in combination with medications (including antibiotics and other antimicrobial drugs) used to treat urogenital diseases. It is recommended to simultaneously use vitamins E and C, which enhance the effect of interferon. Non-narcotic analgesics and anticholinesterase drugs enhance the effect of anesthesin. Anestezin reduces the antibacterial activity of sulfonamides.

METHOD OF APPLICATION AND DOSAGE Infectious and inflammatory diseases of the urogenital tract in women. 1 suppository (250,000 IU or 500,000 IU depending on the severity of the disease) vaginally 2 times a day every day for 10 days. In severe forms, 1 suppository 3 times a week, every other day, for 1-3 months. Infectious and inflammatory diseases in men. Rectally, 1 suppository (500,000 IU or 1,000,000 IU depending on the severity of the disease) 2 times a day for 10 days.

OVERDOSE No cases of overdose with Genferon have been reported.

SPECIAL INSTRUCTIONS No data available.

STORAGE CONDITIONS At a temperature of 2 to 8°C, keep out of the reach of children

Adverse reactions

Treatment with Genferon 10,000,000 IU can lead to non-standard responses of the body:

• headache attacks, decreased levels of leukocytes and platelets in the blood;
• painful sensations in joints and bones;
• active work of sweat glands, increased temperature;
• loss of appetite, rapid fatigue;
• skin itching, rashes, and the appearance of red spots.

These symptoms are reversible and spontaneously disappear three days after stopping the suppositories.

Features of therapy

The instructions recommend the following procedures with Genferon:

1. Infectious and inflammatory pathologies of the genitourinary tract in women - depending on the disease, a suppository twice a day, for 10 days. Chronic and long-term forms of diseases - 1 suppository every 24 hours, for 1-3 months.
2. Lesions of the urogenital tract in men of an infectious-inflammatory nature - 1 suppository in the morning and evening, for 10 days.

The abstract does not indicate any reported cases of overdose. If a large amount of medication is accidentally used, therapy is stopped for 24 hours, then the patient should return to the previously prescribed regimen. If the treatment has caused non-standard symptoms, the patient should attend a consultation with a doctor and describe in detail the changes that have occurred. In some cases, it is necessary to replace the drug with an analogue.

Genferon Light suppositories 125000IU+5mg No. 10

A country

Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.

Active substance

Interferon alpha-2b + Taurine

Compound

Interferon alpha-2b, taurine.

pharmachologic effect

Has local and systemic effects. The drug contains recombinant human interferon alpha-2b. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon. Taurine helps to normalize metabolic processes and tissue regeneration, has a membrane-stabilizing and immunomodulatory effect. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. With rectal administration of the drug, high bioavailability of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of elimination of α-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.

Indications for use

For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women. As a component of complex therapy - for the treatment of other infectious diseases of viral etiology.

Mode of application

The drug can be used both vaginally and rectally. The method of administration, dosage and course duration depend on age, the specific clinical situation and are determined by the attending physician.

Interaction

The drug is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect

Side effect

Local allergic reactions (itching and burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor. Phenomena that occur when using all types of interferon alfa-2b may be observed, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia. In these cases, it is recommended to consult your doctor to decide whether to discontinue the drug or reduce the dose.

Contraindications

Individual intolerance to interferon and other substances included in the drug. With caution: Exacerbation of allergic and autoimmune diseases. Use during pregnancy and lactation: Clinical studies have proven the effectiveness and safety of the drug in the second and third trimesters of pregnancy. The safety of using the drug in the first trimester of pregnancy has not been studied.

Overdose

If you accidentally administer more suppositories at a time than were prescribed by your doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.

special instructions

The drug does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).

Nuances of interaction and manufacturer's instructions

The instructions indicate the following features:

• taking vitamins C and B enhances the activity of Genferon;
• the bactericidal and bacteriostatic activity of sulfonamides decreases when combined with benzocaine;
• Non-narcotic analgesics improve the effectiveness of benzocaine.

The greatest results with therapy with Genferon are recorded when combined with antimicrobial medications. The drug must be used with caution during menstruation due to the lack of sufficient clinical trials.

The drug is incompatible with alcohol; you should avoid drinking alcohol during therapeutic procedures. In the 2-3 trimester of pregnancy, the medication is used when obsessive itching, discomfort and other symptoms occur caused by an infectious-inflammatory lesion of the genitourinary tract.

Use of the drug Genferon in the treatment of patients with chronic urethroprostatitis due to STIs

A.I. Neymark, I.I. Klepikova. Barnaul

Chronic prostatitis affects 40 to 70% of men of reproductive age. This is the most common urological disease in men under 50 years of age and the third most common (after adenoma and prostate cancer) in people over 50 years of age. About 85% or more of cases of chronic prostatitis are caused by microbial factors, of which more than half are the result of hidden urogenital infections, i.e. About 50% of prostatitis, according to its etiological factor, is a complication of STIs.

The problem of treating chronic urethroprostatitis due to STIs remains relevant, despite all the existing specific treatment methods. It is not always effective and safe and leads to the patient’s recovery.

In this connection, the purpose of this study was to assess the effectiveness and safety of the use of the drug geneferon in the treatment of patients with chronic urethroprostatitis due to STIs.

The study included 30 patients, aged from 18 to 55 years, with a disease duration of at least 6 months without concomitant organ pathology. Patients were divided into 2 groups depending on the treatment protocol.

The drug genferon was prescribed 1 suppository at a dose of 1,000,000 IU rectally 2 times a day for 10 days. All patients underwent: medical history, clinical examination, registration of concomitant therapy, bacteriological examination of the esophagus and three portions of urine (Mears and Stamey test), microscopic examination of the esophagus, PCR method for examining a smear from the urethra for the presence of sexually transmitted pathogens (chlamydia, mycoplasma) , ureaplasma, gardnerella). Assessment of symptoms of chronic prostatitis using the NIHCPSI scale.

Based on the treatment performed, the following results were obtained. All patients had 1 and 2 gr. During bacteriological examination of prostate secretions and three portions of urine before and after treatment, nonspecific flora was not detected or its presence was determined to be diagnostically insignificant <104 μ/ml. An exception was one patient of group 2, in whom bacteriological examination of prostate secretions before treatment revealed E. Colli in a titer exceeding normal values. After treatment, this indicator was within normal limits. According to the PCR reaction, in patients of both groups before treatment, in 100% of cases the presence of a mixed infection (ureaplasma, chlamydia, mycoplasma, gardnerella) is determined in varying percentages. After treatment, in 4 patients of the first group, a relapse of infection was determined (2 patients with ureaplasma; 1 with mycoplasma; 1 with gardnerella), which amounted to 26.6%, in contrast to patients in group 2, where no relapse of infection was observed. When assessing the clinical symptoms of chronic prostatitis using the NIHCPSI scale in patients 1 gr. after treatment, a less pronounced but present manifestation of some symptoms of chronic prostatitis (recurrent pain in the perineum, discomfort in the urethra) remains, in contrast to patients of group 2 who received the drug genferon. On average, the NIH-CPSI score before treatment in the first group was 17.6, and 5.6 one month after the end of therapy. In the group of patients who received geneferon: before treatment, 16.3, after therapy, 1.0.

Table 1 Treatment provided in study groups

Thus, the use of the drug genferon in the complex treatment of patients with chronic urethroprostatitis against the background of STIs makes it possible to increase the effectiveness of treatment of this pathology, which is manifested by the absence of relapse of STIs and normalization of clinical symptoms in a shorter period of time, i.e. absence of symptoms of chronic prostatitis after treatment.

Topics and tags

Prostatitis

Comments

To post comments you must log in or register

Analogs

If unusual reactions of the body or signs of intolerance to the component composition occur, the drug requires replacement. The list of analogues is presented:

• Vitaferon, Viferon, Viferon-Feron;
• Laferobion, Laferon Farmbiotek, Kipferon;
• Alfarekin, Alfarona, Bioferon;
• Virogel, Gerpferon, Grippferon;
• Introbion interferon alpha-2b, Intron A;
• Lipoferon, Okoferon, Realdiron, etc.

The selection of a suitable remedy is carried out by the attending physician.

Reviews

On the forums there are both neutral and positive responses about Genferon. Most reviews are related to treatment procedures in women during therapy for HPV, herpetic and cytomegalovirus infections. Good clinical results occur when treated with suppositories of 1 million IU.

Deterioration in well-being and an increase in temperature are associated with large dosages, especially when using suppositories for minors. To avoid the development of adverse reactions, the patient must strictly follow the doctor’s instructions, without deviations from the original regimen.